These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38397992)

  • 41. Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.
    De Corso E; Montuori C; Settimi S; Mele DA; Cantiani A; Corbò M; Cantone E; Paludetti G; Galli J
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
    Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of intranasal corticosteroids in chronic rhinosinusitis with nasal polyposis treated with dupilumab.
    Pecorari G; Piazza F; Borgione M; Prizio C; Galli Della Mantica G; Garetto M; Gedda F; Riva G
    Am J Otolaryngol; 2023; 44(5):103927. PubMed ID: 37245323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.
    Chromy D; Bartosik T; Brkic FF; Quint T; Tu A; Eckl-Dorna J; Schneider S; Bangert C
    J Dermatol; 2023 Jan; 50(1):89-93. PubMed ID: 36177732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review.
    Domínguez-Ortega J; Mullol J; Álvarez Gutiérrez FJ; Miguel-Blanco C; Castillo JA; Olaguibel JM; Blanco-Aparicio M
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100174. PubMed ID: 37915724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab.
    Piazzetta GL; Lobello N; Chiarella E; Rizzuti A; Pelaia C; Pelaia G; Lombardo N
    J Pers Med; 2023 Sep; 13(9):. PubMed ID: 37763171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A "Real-Life" Observational Study in Naïve and Post-Surgical Patients.
    Ottaviano G; Saccardo T; Roccuzzo G; Bernardi R; Chicco AD; Pendolino AL; Scarpa B; Mairani E; Nicolai P
    J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
    Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
    Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
    Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
    Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.
    Fokkens W; Van Der Lans R; Reitsma S
    Expert Opin Biol Ther; 2021 May; 21(5):575-585. PubMed ID: 33724109
    [No Abstract]   [Full Text] [Related]  

  • 53. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.
    Heffler E; Saccheri F; Bartezaghi M; Canonica GW
    Clin Transl Allergy; 2020; 10():25. PubMed ID: 32607141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study.
    Higo H; Ichikawa H; Arakawa Y; Mori Y; Itano J; Taniguchi A; Senoo S; Kimura G; Tanimoto Y; Miyake K; Katsuta T; Kataoka M; Maeda Y; Kiura K; Miyahara N; Okayama Respiratory Disease Study Group Ordsg
    J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
    Bachert C; Laidlaw TM; Cho SH; Mullol J; Swanson BN; Naimi S; Classe M; Harel S; Jagerschmidt A; Laws E; Ruddy M; Praestgaard A; Amin N; Mannent LP
    Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1649-1661. PubMed ID: 37322842
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis.
    Pelaia C; Lombardo N; Busceti MT; Piazzetta G; Crimi C; Calabrese C; Vatrella A; Pelaia G
    J Asthma Allergy; 2021; 14():1165-1172. PubMed ID: 34594115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare].
    Larin RA; Mokeeva PP; Grishin AS
    Vestn Otorinolaringol; 2023; 88(2):51-58. PubMed ID: 37184555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
    Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
    Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.